


# Oncology

International Journal of  
Cancer Research and Treatment




S. Karger  
Medical and Scientific Publishers  
Basel · Freiburg · Paris ·  
London · New York ·  
New Delhi · Bangkok · Beijing ·  
Tokyo · Kuala Lumpur ·  
Singapore · Sydney

**KARGER**

An essential update on uveal melanoma therapy

Ophthalmology, Oncology, Cell Biology, Immunology,  
Pathology, Radiology



# Current Concepts in Uveal Melanoma

**Editors**  
**Martine J. Jager**  
**Laurence Desjardins**  
**Tero Kivelä**  
**Bertil E. Damato**

Uveal melanoma is an aggressive form of cancer that can involve the iris, the ciliary body, and/or the choroid, which is the main location of this tumor. Patients often wish to be informed about treatment choices and the results of different approaches. Important current clinical questions are whether a biopsy should be taken of choroidal melanomas, what should be done with this biopsy, and whether high-risk patients should be screened regularly.

This volume describes the clinical characteristics of uveal melanoma along with the different current techniques available for treatment, such as radioactive plaque treatment, proton beam therapy, and local tumor resection. Furthermore, techniques for taking biopsies and characterizing biopsy material are demonstrated. Future therapies such as anti-VEGF treatment and options for the treatment of metastases are also discussed.

Residents with an interest in ocular oncology, ophthalmologists or physicians dealing with uveal melanoma, as well as patients wishing to know more about this malignancy will find a topical update on uveal melanoma in this publication.

## Contents

Preface: **Jager, M.J.; Desjardins, L.; Kivelä, T.; Damato, B.E.**  
Diagnosis of Uveal Melanoma: **Kivelä, T.**  
Treatment Selection for Uveal Melanoma: **Damato, B.E.**  
Ruthenium-106 Brachytherapy: **Pe'er, J.**  
Treatment of Uveal Melanoma by Accelerated Proton Beam: **Desjardins, L.; Lumbroso-Le Rouic, L.; Levy-Gabriel, C.; Cassoux, N.; Dendale, R.; Mazal, A.; Delacroix, S.; Sastre, X.; Plancher, C.; Asselain, B.**  
Stereotactic Photon Beam Irradiation of Uveal Melanoma: **Zehetmayer, M.**  
Local Resection of Uveal Melanoma: **Damato, B.E.**  
Biopsies in Uveal Melanoma: **Midena, E.; Parrozzani, R.**

Analysis of Intraocular Biopsies: **Coupland, S.E.**  
Antiangiogenic Therapy in Uveal Melanoma: **el Filali, M.; van der Velden, P.A.; Luyten, G.P.M.; Jager, M.J.**  
Immunotherapy of Uveal Melanoma: **Bosch, J.J.**  
Genetic Determinants of Uveal Melanoma: **Couturier, J.; Saule, S.**  
Therapeutic Options in Metastatic Uveal Melanoma: **Mariani, P.; Servois, V.; Piperno-Neumann, S.**

[www.karger.com/deoph](http://www.karger.com/deoph)

## Developments in Ophthalmology, Vol. 49

Series Editor: Bandello, F. (Milan)  
ISSN 0250-3751 / e-ISSN 1662-2790

### Current Concepts in Uveal Melanoma

Editors: Jager, M.J. (Leiden); Desjardins, L. (Paris); Kivelä, T. (Helsinki); Damato, B. (Liverpool)  
VIII + 186 p., 37 fig., 23 in color, 12 tab., hard cover, 2012  
CHF 224.- / EUR 187.- / USD 264.00  
Prices subject to change  
EUR price for Germany, USD price for USA only  
ISBN 978-3-8055-9790-6  
e-ISBN 978-3-8055-9791-3

Please send: \_\_\_\_ copy/ies

Postage and handling free with prepayment

### Payment:

Please charge to my credit card  
☐ American Express ☐ Diners ☐ Eurocard  
☐ MasterCard ☐ Visa

Card No.:

Exp. date:

CVV/CVC

(3 digits in the signature field on the back of Visa and MasterCard)

☐ Check enclosed ☐ Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Fax: +41 61 306 12 34

S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)  
E-Mail orders@karger.ch, [www.karger.com](http://www.karger.com)

Name/Address:

Date:

Signature:

**KARGER**

---

# Oncology

**International Journal of Cancer Research and Treatment**

Founded 1948 as 'Oncologia' by H.R. Schinz

Continued by V. Richards (1967–1975), H. Wrba (1976–1992), P.P. Carbone (1993–2002),  
D.L. Trump (2002–2007)

---

**Editor-in-Chief**

M. Markman, Philadelphia, Pa.

---

**Associate Editor**

P. Dufour, Strasbourg

---

**Regional Editor Japan**

O. Hino, Tokyo

---

**Editorial Board**

A.B. Benson, Chicago, Ill.  
A. Chang, Singapore  
A.L. Cheng, Taipei  
J.F. Cleary, Madison, Wisc.  
M.S. Ernstoff, Lebanon, N.H.  
M. Fakih, Ann Arbor, Mich.  
J.J. Grau, Barcelona  
H. Gronemeyer, Illkirch  
D.F. Hayes, Ann Arbor, Mich.  
C.S. Johnson, Buffalo, N.Y.  
M.J. Kelley, Durham, N.C.  
P.J. Loehrer, Indianapolis, Ind.  
J.R. Marshall, Buffalo, N.Y.  
S. Monfardini, Milan  
R. Nagler, Haifa  
R. Ohno, Nagoya  
B. Pestalozzi, Zurich  
H.M. Pinedo, Amsterdam  
E.A. Repasky, Buffalo, N.Y.  
A. Semczuk, Lublin  
C.N. Sternberg, Rome  
R. Stupp, Lausanne  
M.S. Tallman, Chicago, Ill.  
S. Tanaka, Hiroshima  
M. Tian, Houston, Tex.  
D.L. Trump, Buffalo, N.Y.  
T. Wiegel, Ulm  
W. Yasui, Hiroshima  
H. Zhang, Hangzhou City

---

**KARGER**

Printed in Switzerland  
on acid-free and non-aging  
paper (ISO 9706) by  
Reinhardt Druck, Basel

Appears monthly:  
2 volumes per year  
(12 issues)

### Submission

Original papers and reviews written in English are considered for publication. **Manuscripts should be submitted to 'Oncology' online.** For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at [www.karger.com/ocl](http://www.karger.com/ocl), where you will also find a link to the **Submission Website**. Names, postal and e-mail addresses of at least four experts in the appropriate area of research must accompany each manuscript. Selected scientists will be invited to act as referees. Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject. Should you have any problems with your submission, please contact:

Dr. M. Markman  
S. Karger AG  
Editorial Office 'Oncology'  
P.O. Box  
CH-4009 Basel (Switzerland)  
Tel. +41 61 306 1359  
Fax +41 61 306 1434  
E-Mail [ocl@karger.ch](mailto:ocl@karger.ch)

Mailing address for courier deliveries only:  
Allschwilerstr. 10  
CH-4055 Basel (Switzerland)

### Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. The editors reserve the right to improve style and, if necessary, return the manuscript for rewriting to the author. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Oncology' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

All manuscripts originating from non-English speaking countries must be revised by a professional linguistic reviewer and it must be evident from the covering letter that this has been done.

The editor reserves the right to reject papers based on priorities and space availability in the journal.

### Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the text of the article.

### Ethical and Legal Prerequisites

Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925-926]. Accordingly, the subject's informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject's identity is to be avoided.

### Categories of Manuscripts

*Reviews* are comprehensive, state-of-the-art analyses and investigations of important clinical problems. Reviews must include a critical discussion of the reported data and give a clear conclusion with the potential impacts on the standard of care. Reviews may be invited by the Editor, or they may be unsolicited submissions. Reviews are not subject to page charges. The maximum length of manuscripts in this category will be 5,000 words for text and tables (a table = 250 words per page), with a maximum of 5 tables and 50 references.

*Clinical Studies and Clinical Translational Research Articles* are full-length research papers which will be considered for the journal. These articles cover topics relevant to clinical and translational studies in all oncological fields. Note that manuscripts presenting laboratory-based research efforts must address a clinically relevant issue (Translational Research).

*Short Communications* will focus on descriptions of important toxicities of novel therapies and highly unique oncology-related medical management issues. The maximum length of manuscripts in this category will be 1,000 words.

*Clinical Trial Notes* are designed for brief discussions of clinical trials, with a particular focus on phase 1, phase 1/2, and phase 2 studies. Priority in this section will not be for studies with a 'positive result', but rather for well-conceived and conducted clinical research efforts. The maximum length of manuscripts submitted in this category will be 1,500 words, with a maximum of 2 tables and 1 figure. The paper should be divided into four sections: Introduction, Methods, Results, Discussion. Note that all manuscripts submitted in this category will undergo rapid review for acceptance or rejection.

*Reducing the Worldwide Burden of Cancer* are country reports describing a variety of regional, national or international efforts that focus on the unique aspects of the epidemiology of cancer, and the delivery of educational messages, preventive services, and oncology-related care within the developing world. Papers submitted for this section benefit from a higher quota of free pages. There are no page charges for papers of 8 or fewer printed pages. Each additional complete or partial page is charged to the author at CHF 325.00.

*Editorials* provide comments on papers published in Oncology. They are usually invited by the Editor.

### Arrangement

*Title page:* The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

*Full address:* The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

*Key words:* Please supply 3-10 key words in English that reflect the content of the paper.

*Abstract:* Papers submitted to the sections Reviews, Clinical Studies, Clinical Translational Research Articles, Clinical Trial Notes and Reducing the World-

wide Burden of Cancer need an abstract of up to 200 words. Abstracts are recommended, but optional, for Short Communications and Editorials. Abstracts of papers submitted for publication that have clinical implications using human materials should be structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s).

*Footnotes:* Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

*Tables and illustrations:* Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author's name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800-1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions on the Submission Website at [www.karger.com/ocl](http://www.karger.com/ocl)).

### Color illustrations

**Online edition:** Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

**Print edition:** Up to 6 color illustrations per page can be integrated within the text at CHF 800.- per page.

### References

In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as 'unpublished data' and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals ([www.icmje.org](http://www.icmje.org)).

### Examples

(a) *Papers published in periodicals:* Chatel J-M, Bernard H, Orson FM: Isolation and characterization of two complete Ara h 2 isoforms cDNA. *Int Arch Allergy Immunol* 2003;131:14-18.

(b) *Papers published only with DOI numbers:* Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. *Int Arch Allergy Immunol* DOI: 10.1159/000063858.

(c) *Monographs:* Matthews DE, Farewell VT: *Using and Understanding Medical Statistics*, ed 3, revised. Basel, Karger, 1996.0

(d) *Edited books:* Cochrane AL, Ricardo SD: *Oxidant stress and regulation of chemokines in the develop-*

ment of renal interstitial fibrosis; in Razzaque MS, Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. Basel, Karger, 2003, vol 139, pp 102–119.  
*Reference Management Software*: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

#### Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at [www.doi.org](http://www.doi.org).

#### Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files,

Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

#### Author's Choice™

Karger's Author's Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at [www.karger.com](http://www.karger.com). The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at [www.karger.com/authors\\_choice](http://www.karger.com/authors_choice).

#### NIH-Funded Research

The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy is available at <http://publicaccess.nih.gov/policy.htm>

#### Self-Archiving

Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-ref-

ereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

#### Page Charges

There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 9 manuscript pages (including tables, illustrations and references).

#### Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.

#### Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.


*A new vision to understanding medicine*

# Handbook of Clinical Gender Medicine

**Editors:** Karin Schenck-Gustafsson (Stockholm),  
Paula R. DeCola, Donald W. Pfaff (New York, N.Y.),  
David S. Pisetsky (Durham N.C.)

In well-referenced chapters, experts cogently and concisely explain how the incorporation of gender issues into research can affect the medical understanding and treatment of heart disease, osteoporosis, arthritis, pain as well as malaria among other conditions.

This intriguing and unique medical textbook provides readers with a valuable new perspective on how to incorporate gender issues into the different branches of medicine.



XVI + 522 p., 62 fig., 4 in color, 63 tab.,  
soft cover, 2012  
CHF 69.– / EUR 51.– / USD 69.00  
ISBN 978–3–8055–9929–0  
e-ISBN 978–3–8055–9930–6

Prices subject to change  
EUR price for Germany,  
USD price for USA only

More information and sample essays at:

**[www.karger.com/Gender\\_Medicine](http://www.karger.com/Gender_Medicine)**

S. Karger AG, P.O. Box  
CH–4009 Basel  
(Switzerland)  
Fax: +41 61 306 12 34  
E-Mail [orders@karger.ch](mailto:orders@karger.ch)  
[www.karger.com](http://www.karger.com)

**KARGER**

**KARGER**

Fax +41 61 306 12 34  
E-Mail [karger@karger.ch](mailto:karger@karger.ch)  
[www.karger.com](http://www.karger.com)

© 2013 S. Karger AG, Basel

The Guidelines for Authors are available at:  
[www.karger.com/ocl\\_Guidelines](http://www.karger.com/ocl_Guidelines)

**ISSN Print Edition:** 0030-2414  
**ISSN Online Edition:** 1423-0232

**Journal Homepage:** [www.karger.com/ocl](http://www.karger.com/ocl)

**Publication Data:** 'Oncology' is published 12 times a year. Volumes 84 and 85, each with 6 issues, appear in 2013.

**Copyright:** © 2013 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.

**Disclaimer:** The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

**Subscription Rates:** Subscriptions run for a full calendar year. Prices are given per year.

*Personal subscription:*

Print or Online	Print+Online combined
CHF 1622.–	CHF 1718.–
EUR 1308.–	EUR 1386.–
USD 1606.00	USD 1702.00
<b>postage and handling</b> (added to print and print+online)	
CHF 86.40 Europe, CHF 124.80 Overseas	
EUR 67.20	
USD 115.20	

*Institutional subscription:*

Print or Online	Print+Online combined
CHF 3244.–	CHF 3568.–
EUR 2616.–	EUR 2878.–
USD 3212.00	USD 3532.00
<b>postage and handling</b> (added to print and print+online)	
CHF 108.– Europe, CHF 156.– Overseas	
EUR 84.–	
USD 144.00	

*Airmail surcharge:* CHF 105.– / USD 99.00

**Back Volumes and Single Issues:** Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at [service@karger.ch](mailto:service@karger.ch).

**Bibliographic Indices:** This journal is regularly listed in bibliographic services, including *Current Contents®* and PubMed/MEDLINE.

**Photocopying:** This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to

Copyright Clearance Center Inc.  
222 Rosewood Drive  
Danvers, MA 01923 (USA)

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH-4009 Basel (Switzerland).

### Subscription Orders:

Orders can be placed at agencies, bookstores, directly with the Publisher

### S. Karger AG

Medical and Scientific Publishers  
P.O. Box  
CH-4009 Basel  
Switzerland  
(for courier services only:  
Allschwilerstrasse 10  
CH-4055 Basel)  
t: +41 61 306 11 11  
f: +41 61 306 12 34  
e: [karger@karger.ch](mailto:karger@karger.ch)  
w: [www.karger.com](http://www.karger.com)

or further Karger offices  
or representatives:

### Germany

**S. Karger GmbH**  
Postfach  
79095 Freiburg  
Deutschland  
(Hausadresse: Wilhelmstrasse 20A,  
79098 Freiburg)  
t: +49 761 45 20 70  
f: +49 761 45 20 714  
e: [information@karger.de](mailto:information@karger.de)  
w: [www.karger.de](http://www.karger.de)

### Japan

**Karger Japan, Inc.**  
Shiba Daimon Asahi Bldg. 2F  
1-2-23 Shiba Daimon  
Minato-ku  
Tokyo 105-0012  
Japan  
t: +81 3 6435 6242  
f: +81 3 6435 6244  
e: [publisher@karger.jp](mailto:publisher@karger.jp)  
w: [www.karger.jp](http://www.karger.jp)

### USA

**S. Karger Publishers, Inc.**  
26 West Avon Road  
P.O. Box 529  
Unionville, CT 06085  
USA  
Toll free: +1 800 828 5479  
t: +1 860 675 7834  
f: +1 860 675 7302  
e: [karger@snet.net](mailto:karger@snet.net)

### France

**Librairie Médi-Sciences Sarl**  
36, bd de Latour-Maubourg  
75007 Paris  
France  
t: +33 (0) 1 45 51 42 58  
f: +33 (0) 1 45 56 07 80  
e: [librairie@medi-sciences.fr](mailto:librairie@medi-sciences.fr)  
w: [www.medi-sciences.fr](http://www.medi-sciences.fr)

Gulf Council Countries, Iran,  
Middle East, North Africa, Turkey  
**Trans Middle East International  
Distribution Co. Ltd. (KaSha)**  
168 B, King Abdullah the 2nd Street  
Daboog Building 2nd Floor  
Daboog Area  
P.O. Box 2376  
Amman 11953  
Jordan  
t: +962 6 515 3467  
f: +962 6 541 1336  
e: [info@kasha.cc](mailto:info@kasha.cc)  
w: [www.KaShaonline.com](http://www.KaShaonline.com)

South East Asia, China and Taiwan  
**Karger Regional Office (Malaysia)**

CEO Suite Kuala Lumpur  
Quill 7, 27th Floor  
Jalan Stesen Sentral 5  
KL Sentral  
Kuala Lumpur 50470  
Malaysia  
t: +60 3 2776 6803  
f: +60 3 2776 6999  
e: [service@karger.cn](mailto:service@karger.cn); [r.chew@karger.cn](mailto:r.chew@karger.cn)

### Karger China

10th Floor, Twin Towers (East)  
B12 Jianguomenwai Avenue  
Beijing 100022  
China  
t: +86 10 5123 5033  
f: +86 10 5123 5122  
e: [service@karger.cn](mailto:service@karger.cn); [r.chew@karger.cn](mailto:r.chew@karger.cn)  
w: [www.karger.cn](http://www.karger.cn)

India, Bangladesh, Sri Lanka  
**Medscience India**

Plot No. 17, Yusuf Sarai Market  
B.L. Glass Building, 2nd Floor  
Sri Aurobindo Marg  
New Delhi 110 016  
India  
t: +91 11 46029 633  
f: +91 11 46029 634  
c: +91 98 91052 128  
e: [medsci.india@gmail.com](mailto:medsci.india@gmail.com)

### Change of Address:

Both old and new address should be sent to the subscription source.

---

# Contents

[See the journal website for contents](#)



SOCIÉTÉ INTERNATIONALE  
D'ONCOLOGIE PÉDIATRIQUE  
**SIOP**  
INTERNATIONAL SOCIETY  
OF PAEDIATRIC ONCOLOGY

# 45th Congress of the International Society of Paediatric Oncology

## 25th-28th September 2013


Hong Kong Convention  
and Exhibition Centre

Hong Kong, China

Save the Date



Scan this code with  
your smart phone:



Need a code reader for your phone?  
<http://get.neoreader.com>

Congress Organizer



1-3 Rue de Chantepoulet, PO Box 1726, CH-1211 Geneva 1  
Switzerland, Tel: + 41 22 908 0488; Fax: + 41 22 906 9140  
E-mail: [siop@kenes.com](mailto:siop@kenes.com)

© Kenes Group 2012. All rights reserved.

[www.kenes.com/siop](http://www.kenes.com/siop)





**ICACT**  
24<sup>TH</sup> INTERNATIONAL CONGRESS  
ON ANTI-CANCER TREATMENT

Paris, France  
*Palais des Congrès*

5-7<sup>th</sup>  
February 2013

# A World Leading Educational meeting

70 Speakers

22 Concurrent Sessions

80 Topics    20 Meet the Professor

For further information, kindly visit [www.icact.com](http://www.icact.com) or send us email via [infos@im-events.com](mailto:infos@im-events.com).  
We look forward to your participation in the 24<sup>th</sup> International Congress on Anti-Cancer Treatment





# 12-ICML

## 12th International Conference on Malignant Lymphoma

Lugano, Switzerland, June 19–22, 2013

---

### Deadlines:

<b>Abstract Submission</b>	February 28, 2013
<b>Early Registration</b>	on or before March 15, 2013
<b>Late Registration</b>	from March 16, 2013 (up to 3000 attendees)



For information, programme and on-line registration:  
**[www.lymphcon.ch](http://www.lymphcon.ch)**



## 5<sup>th</sup> International Conference on Drug Discovery & Therapy

February 18 - 21, 2013, Dubai, UAE

### CONFERENCE PRESIDENTS



Prof. Ferid Murad  
(Nobel Laureate)



Prof. Dr. Atta-ur-Rahman  
FRS

### CONFERENCE TRACKS

- Academic CRO/Industrial collaborations in drug discovery
- Anti-Cancer Drug Discovery & Therapy
- Anti-Infectives
- Bioactive Lipids
- Biologics
- Cardiovascular Drug Discovery & Therapy
- Chemistry
- Combinatorial Chemistry
- CNS Drug Discovery & Therapy
- Diabetes and Obesity Drug Discovery & Therapy
- Drug Delivery & Targeting
- Drug Discovery in Preclinical Research
- Drug Metabolism
- Enabling Technologies
- Genomics
- Green Techniques for Medicinal Chemistry
- High-throughput Screening & Laboratory automation
- Hot Topics in Drug Targets
- Hot Topics in HIV Research
- Hot Topics in Medicinal Chemistry
- Hot Topics in Natural Products
- Inflammation and Immunology
- Innovative Drug Discovery and Nanotechnology
- In-silico Drug Design and in-silico screening
- Medical Imaging
- Nutraceutical Drug Discovery & Therapy
- Pharmaceutical Biotechnology
- Pharmaceutical Research & Development
- Pharmacogenomics
- Process Chemistry and Drug Manufacturing
- Protein and Peptide Sciences
- Proteomics & Bioinformatics
- Pulmonary Drug Discovery & Therapy
- Recent Advances in Patient Treatment and Care
- Recent Advances in Spectroscopy
- Regenerative Medicine
- Stereoselective Synthesis of Bioactive Compounds
- Structural Biology
- Translational Medicine
- Women's Health Drug Discovery & Therapy

## Be a Part of the Drug Discovery Venture!

### PARTICIPATING NOBEL LAUREATES



Ferid Murad



Jean-Marie Lehn

### KEY BENEFITS OF ATTENDING

- Explore Cutting Edge Drug Discoveries
- Gain Networking Opportunities
- Tracks on Pre-Clinical & Therapeutic Themes
- Earn CME Accreditation (under application in UAE)
- Commercial Exhibition

### TO KNOW MORE ABOUT

- Registration
- Submission of Abstract
- Sponsorship & Exhibition Opportunities

please visit the event website

**[www.icddt.com](http://www.icddt.com)**

**Deadline for Submissions for  
Oral Presentation or Poster Session  
15th January 2013**

NATIONAL ORGANIZER



HIGHER  
COLLEGES OF  
TECHNOLOGY

INTERNATIONAL ORGANIZER



Contact: ICDDT 2013 Secretariat

PO Box 121223, SAIF Zone, Sharjah, U.A.E.

Tel: +971-6-5575783, Fax: +971-6-5575784

E-mail: [info@icddt.com](mailto:info@icddt.com)

[www.bionanomed.at](http://www.bionanomed.at)

**APPLY  
NOW!**

**NANOTECHNOLOGY ENABLES PERSONALIZED MEDICINE**

**BioNanoMed  
2013**

**4<sup>th</sup> International Congress  
NANOTECHNOLOGY, MEDICINE & BIOLOGY**

**13 - 15 MARCH 2013, KREMS/AUSTRIA**

**TOPICS**

- Novel Nanomedical Solutions - Advances in Nanomedicine
- Regenerative Nanomedicine
- Nano-Bio-Technology based Diagnostics
- Nano-Bio-Technology based Therapy

**THEMATIC SESSIONS**

- Nano-Imaging-Technologies in Medicine
- Nanotechnology in Artificial Organ Support
- Aspects of NanoSafety

**POSTER AWARD - EXHIBITION - CREDIT POINTS**

Deadline for oral abstracts: 14 December 2012

Deadline for Poster abstracts: 1 March 2013



4<sup>eme</sup>



# Monaco Age Oncologie

Sporting d'Hiver

Monaco

21/22 mars 2013

mao@publiccreations.com

BIOLOGIE DU CANCER ET DU VIELLISSEMENT  
CANCER DU SEIN METASTATIQUE  
AGE : UN FACTEUR DE TOXICITE  
UCOG-RECHERCHE CLINIQUE  
LYMPHOMES AGRESSIFS  
LE JOG A LU POUR VOUS  
TUMEUR CEREBRALE  
CANCER DE L'OVAIRE  
THERAPIES CIBLEES  
RADIOETHERAPIE  
BIOSIMILAIRES  
ANEMIE

 [www.mao-monaco.org](http://www.mao-monaco.org)



**SAVE THE DATES**


**MARCH 7-10, 2013    BARCELONA, SPAIN**

- Whole genome sequencing vs. selected genes NGS
- Epigenetic vs. Genomics
- Design clinical trial in an era of personalized oncology
- Treatment decisions based on gene mutations vs. disease origin
- Gene signatures for disease classification
- Gene signatures for disease classification
- Histopathology vs. Modern Molecular DX
- CTC as a prognostic and treatment monitoring tool
- Gene to drug development
- Small molecules vs. Abs



• Gene signatures for disease classification

[www.comtecmed.com/conpo](http://www.comtecmed.com/conpo) | [conpo@comtecmed.com](mailto:conpo@comtecmed.com)



# Inflammation and Cancer

Editors  
G. Tiegs  
A.W. Lohse  
R. Thimme  
C. Trautwein

## Inflammation and Cancer

Editors: Tiegs, G.; Lohse, A.W. (Hamburg);  
Thimme, R. (Freiburg); Trautwein, C. (Aachen)  
96 p., 20 fig., 3 tab., soft cover, 2012  
CHF 48.– / EUR 40.– / USD 56.00  
Prices subject to change  
EUR price for Germany, USD price for USA only  
ISBN 978-3-318-02242-1  
e-ISBN 978-3-318-02243-8

Special Topic Issue:  
**Digestive Diseases**  
**Vol. 30, No. 5 (2012)**  
Included in subscription



Dear Librarian

I have reviewed this publication and  
would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop,  
subscription agency, directly with the publisher  
or through a Karger distributor.

## Contents

• Preface: Tiegs, G.

## Viral Hepatitis

- Promotion of Hepatocellular Carcinoma by  
Hepatitis C Virus: **Bühler, S.; Bartenschlager, R.**
- Lymphotoxin, NF- $\kappa$ B, and Cancer: The Dark Side of  
Cytokines: **Bauer, J.; Namineni, S.; Reisinger, F.; Zöller, J.;  
Yuan, D.; Heikenwälder, M.**

## Immunology

- Colitis and Colorectal Cancer: **Foersch, S.;  
Waldner, M.J.; Neurath, M.F.**
- Cellular Immune Suppressor Mechanisms in  
Patients with Hepatocellular Carcinoma: **Zhao, F.;  
Koranyi, F.; Greten, T.F.**
- Cellular Immune Responses to Hepatocellular  
Carcinoma: Lessons for Immunotherapy:  
**Schmidt, N.; Neumann-Haefelin, C.; Thimme, R.**

## Cytokines and Intracellular Signaling

- Interleukin-6 Trans-Signaling and Colonic Cancer  
Associated with Inflammatory Bowel Disease:  
**Chalaris, A.; Schmidt-Arras, D.; Yamamoto, K.;  
Rose-John, S.**
- TNF-Dependent Signaling Pathways in Liver  
Cancer: Promising Targets for Therapeutic  
Strategies? **Roderburg, C.; Gautheron, J.; Luedde, T.**
- Adipocytokines and Hepatocellular Carcinoma:  
**Wieser, V.; Moschen, A.R.; Tilg, H.**

## Growth Factors and Regeneration

- TGF- $\beta$  Signaling in Onset and Progression of  
Hepatocellular Carcinoma: **Meindl-Beinker, N.M.;  
Matsuzaki, K.; Dooley, S.**
- Epidermal Growth Factor Receptor Signaling in  
Hepatocellular Carcinoma: Inflammatory  
Activation and a New Intracellular Regulatory  
Mechanism: **Berasain, C.; Nicou, A.; Garcia-Irigoyen, O.;  
Latasa, M.U.; Urtasun, R.; Elizalde, M.; Salis, F.;  
Perugorria, M.J.; Prieto, J.; Recio, J.A.; Corrales, F.J.;  
Avila, M.A.**

The easiest way to order: [www.karger.com/ddi](http://www.karger.com/ddi)

**Karger – Medical and Scientific Publishers**  
CH-4009 Basel, Switzerland  
[orders@karger.ch](mailto:orders@karger.ch), f: +41 61 306 12 34  
[www.karger.com](http://www.karger.com)

Official journal  
of the IAC

The essential resource for today's cytopathologist

# ACTA CYTOLOGICA

The Journal of Clinical Cytology and Cytopathology

Editor-in-Chief

**Marluce Bibbo,**  
Philadelphia, Pa.

Associate Editors

**R. Marshall Austin,**  
Pittsburgh, Pa.

**Thomas A. Bonfiglio,**  
Rochester, N.Y.

**Lukas Bubendorf,** Basel

**Edmund S. Cibas,**  
Boston, Mass.

**Yener S. Erozan,**  
Baltimore, Md.

**David B. Kaminsky,**  
Palm Springs, Calif.

**Robert Y. Osamura,** Tokyo

**Fernando C. Schmitt,**  
Porto


**Volker Schneider,**  
Freiburg i.B.

**Mark E. Sherman,**  
Rockville, Md.

**Diane Solomon,**  
Rockville, Md.

**Alain P. Verhest,** Brussels

**Philippe Vielh,** Villejuif



More information at

**www.karger.com/acy**

- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation



**Acta Cytologica**  
2013: Volume 57  
6 issues per volume  
Language: English  
ISSN 0001-5547 (print)  
ISSN 1938-2650 (online)

Listed in bibliographic services, including  
Current Contents®, PubMed/Medline,  
Science Citation Index, Ulrichs, EMBASE/  
Excerpta Medica

## Selected contributions

- Immunomarkers in Gynecologic Cytology: The Search for the Ideal 'Biomolecular Papanicolaou Test': **Pinto, Á.P.; Degen, M.** (Boston, Mass.); **Villa, L.L.** (São Paulo); **Cibas, E.S.** (Boston, Mass.)
- Reclassifying Formerly Indeterminate Thyroid FNAs Using the Bethesda System Reduces the Number of Inconclusive Cases: **Song, J.Y.; Chu, Y.C.; Kim, L.; Park, I.S.; Han, J.Y.; Kim, J.M.** (Incheon)
- Fine-Needle Cytology and Flow Cytometry Assessment of Reactive and Lymphoproliferative Processes of the Breast: **Vigliar, E.; Cozzolino, I.; Fernandez, L.V.S.; Di Pietto, L.; Riccardi, A.; Picardi, M.; Pane, F.; Vetrani, A.; Troncone, G.; Zeppa, P.** (Napoli)
- Ultrasound Gel Causes Fine Needle Aspiration Artifact? A Clear Choice: **Royer, M.C.; Davidson, D.D.; Dimitrov, R.K.** (Indianapolis, Ind.); **Kuo, C.Y.** (Nashville, Tenn.); **Kokoska, M.S.** (Indianapolis, Ind.)
- Type-Specific Human Papillomavirus DNA Detected in Atypical Glandular Cell Pap Tests: **Mulhem, E.; Amin, M.; Copeland, J.; Sharma, J.; Hunter, S.** (Rochester, Mich.)
- Signet Ring Cell Carcinoma in Urine Cytology: Cytomorphologic Findings and Differential Diagnosis: **Guan, H.; Tatsas, A.D.; Ali, S.Z.** (Baltimore, Md.)
- Discriminant Analysis of Malignant Mesothelioma and Reactive Mesothelium Using Three-Dimensional Nuclear Estimation: **Washiya, K.; Narumi, K.; Noro, T.** (Hiroshima); **Hamakawa, S.** (Kodaira); **Furuta, N.** (Tokyo); **Yoshioka, H.; Watanabe, J.** (Hiroshima)
- Assessment of Fine Needle Aspiration Specimen Adequacy for High-Risk HPV Detection and Genotyping in Oropharyngeal Squamous Cell Carcinoma: **Solomides, C.C.; Bibbo, M.; Wang, Z.-X.** (Philadelphia, Pa.)

Offering an excellent balance of articles on both clinical cytology and cytopathology, *Acta Cytologica* furthers the understanding of cytopathologic processes and facilitates the translation of current research into clinical practice. As the official journal of the International Academy of Cytology and affiliated to over 50 cytology societies around the world, *Acta Cytologica* evaluates new and existing diagnostic applications of scientific advances as well as their clinical correlation. Original papers, review articles, case reports and letters to the editor cover topics from diagnostic cytopathology, gynecologic and nongynecologic cytopathology to fine-needle aspiration, molecular techniques and diagnostic methodologies.

The perfect reference for practical use, *Acta Cytologica* addresses a multidisciplinary audience involved in the clinical practice of cytopathology, cell biology, oncology, interventional radiology, otorhinolaryngology, gastroenterology, urology, pulmonology and preventive medicine.



# Oncology

## Editorial

### 39 Targeted Therapies and Survival: What We Can Learn from Studies in Advanced Renal Cell Carcinoma

Procopio, G.; Verzoni, E.; de Braud, F. (Milan)

## Reviews

### 22 New Insights into the Management of Renal Cell Cancer

Pécuchet, N.; Fournier, L.S.; Oudard, S. (Paris)

### 43 Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment

LoRusso, P.M. (Detroit, Mich.)

## Clinical Studies

### 1 The Clinical Meaning of Intramammary Lymph Nodes

Lee, S.K.; Kim, S.; Choi, M.-Y.; Kim, J.; Lee, J.; Jung, S.P.; Choe, J.-H.; Kim, J.-H.; Kim, J.S.; Kil, W.H.; Lee, J.E.; Nam, S.J. (Seoul)

### 6 Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma

Koschny, R.; Gotthardt, D.; Koehler, C.; Jaeger, D.; Stremmel, W.; Ganten, T.M. (Heidelberg)

### 14 Adjuvant Systemic Chemotherapy with or without Bevacizumab in Patients with Resected Liver Metastases from Colorectal Cancer

Turan, N.; Benekli, M. (Ankara); Koca, D. (Izmir); Ustaalioglu, B.O.; Dane, F. (Istanbul); Ozdemir, N.; Ulas, A. (Ankara); Oztup, I. (Izmir); Gumus, M.; Ozturk, M.A. (Istanbul); Berk, V. (Kayseri); Kucukoner, M. (Diyarbakir); Uner, A. (Ankara); Balakan, O. (Gaziantep); Helvacı, K.; Ozkan, S. (Ankara); Yilmaz, U. (Izmir); Buyukberber, S. (Ankara) for the Anatolian Society of Medical Oncology

### 32 Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis

Dhooge, M.; Coriat, R.; Mir, O.; Perkins, G.; Brezault, C.; Boudou-Rouquette, P.; Goldwasser, F.; Chaussade, S. (Paris)

### 57 Treatment Strategy for Superficial Pharyngeal Squamous Cell Carcinoma Synchronously Combined with Esophageal Cancer

Kaneko, K.; Yano, T.; Minashi, K.; Kojima, T.; Ito, M.; Satake, H.; Yajima, Y.; Yoda, Y.; Ikematsu, H.; Oono, Y.; Hayashi, R.; Onozawa, M.; Ohtsu, A. (Kashiwa)